&nbsp;

BiosimilarsEvaluationToolkit_FR.pdf

Nov 2021

Regimen

BREN

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Intermediate Grade,

Lymphoma - T-cell,

Rare Diseases

Intent: Palliative

Funding:

New Drug Funding Program

Brentuximab Vedotin - Previously Treated Primary Cutaneous Anaplastic Large Cell Lymphoma or Mycosis Fungoides

, Collapse Show fewer tags

Drugs Used:

brentuximab vedotin

... Show more tags

Quick Link(s):

Regimen Monograph

Sep 2024

Document

FormulaSedentaryTime-EN.JPG

Feb 2022

Document

FormulaSedentaryTime-FR.JPG

Feb 2022

Document

FITLabReportsPrimary.pdf

Mar 2022

Document

food-literacy-en.png

Jan 2023

Document

food-literacy-fr.png

Jan 2023

Document

brad-campbell.jpg

Jan 2023

Regimen

FEC+PEMB

Cancer Type:

Breast

Intent: Neoadjuvant

Funding:

New Drug Funding Program

Pembrolizumab - Previously Untreated High-Risk Early-Stage Triple Negative Breast Cancer

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Regimen

BELZ

Cancer Type:

Endocrine,

Pancreatic Neuroendocrine,

Genitourinary,

Renal cell / Kidney

Intent: Curative, Palliative

Funding:

Exceptional Access Program

Belzutifan – For the treatment of adult patients with von Hippel-Lindau (VHL) disease, based on criteria